From system building to global engagement: Current significance of and future directions for rare disease research in China

Tang W

Intractable Rare Dis Res. 2026; 15(1):1-3.

DOI: 10.5582/irdr.2026.01015

Summary Full Text (PDF)

The imperative for national legislation on rare diseases in China: A policy review and call to action

Li Y, Liu Z, Huang R, Liu Y

Intractable Rare Dis Res. 2026; 15(1):4-10.

DOI: 10.5582/irdr.2025.01058

Summary Full Text (PDF)

Progress in the research and pharmacoeconomic evaluation of drugs and devices for rare diseases in China

Hu SL

Intractable Rare Dis Res. 2026; 15(1):11-16.

DOI: 10.5582/irdr.2025.01071

Summary Full Text (PDF)

Health technology assessment and medical insurance access for rare disease drugs in China: A policy review with quantitative insights from publicly available data

Ai DD, Sui BY, Duan CAX, Liu Z, Zhang F, Zhao K

Intractable Rare Dis Res. 2026; 15(1):17-25.

DOI: 10.5582/irdr.2025.01076

Summary Full Text (PDF)

Foods for special medical purposes for the dietary therapy of rare diseases: Current status and future prospects

Zhang T, Wang Y, Shi CP, Zi Y, Cai W, Zhong J

Intractable Rare Dis Res. 2026; 15(1):26-44.

DOI: 10.5582/irdr.2025.01075

Summary Full Text (PDF)

Current status and challenges of biologic targeted therapy for myasthenia gravis in China

Gu S, Zhao C

Intractable Rare Dis Res. 2026; 15(1):45-53.

DOI: 10.5582/irdr.2025.01061

Summary Full Text (PDF)

How to evaluate rare disease policy effectiveness based on policy modeling consistency (PMC) index model: A quantitative assessment of policy implementation in China

Zhao Y, Zhang X, He D, Li Y, Dong R, Gu Y, Xie J

Intractable Rare Dis Res. 2026; 15(1):54-70.

DOI: 10.5582/irdr.2025.01078

Summary Full Text (PDF)

Visualization analysis of the use of traditional Chinese medicine in the diagnosis and treatment of rare diseases in mainland China based on CiteSpace

Shi Y, Xiao SJ, He D

Intractable Rare Dis Res. 2026; 15(1):71-84.

DOI: 10.5582/irdr.2025.01056

Summary Full Text (PDF)

Medical security for rare disease patients in China: Insights from patients with Dravet syndrome

Wu J, Lu X, Gu L, Yang Y, Zhang M, Zhou H, Zhou L, Lan Y, Li J, Mao N

Intractable Rare Dis Res. 2026; 15(1):85-94.

DOI: 10.5582/irdr.2025.01059

Summary Full Text (PDF)

Comparative analysis of adverse event reporting signals between Satralizumab and Inebilizumab in neuromyelitis optica spectrum disorder: A pharmacovigilance study using the FDA Adverse Event Reporting System

Zhao Y, Zhang Y, Yu J, Zhou C, Hao Y, Liu Y, Wang J, Li S, Zhao Z

Intractable Rare Dis Res. 2026; 15(1):95-105.

DOI: 10.5582/irdr.2025.01065

Summary Full Text (PDF)

Multidisciplinary approach to the assessment and management of children with Fabry disease: Insights from the Chinese Children Genetic Kidney Disease Database

Wang J, Liu J, Chen J, Zhang A, Mao J, Shen T, Jiang X, Wang M, Tao Y, Zhao B, Wang X, Li Z, Chen A, Chen C, Zhang B, Zhang D, Zhao L, Zhao Y, Bao Y, Bai L, Liu C, Wang F, Hu F, Chen M, Lv X, Sun S, Shen Q, Xu H

Intractable Rare Dis Res. 2026; 15(1):106-114.

DOI: 10.5582/irdr.2025.01070

Summary Full Text (PDF)

From co-creation to compounding value: A new model of rare disease science communication in China

Chen Y

Intractable Rare Dis Res. 2026; 15(1):115-119.

DOI: 10.5582/irdr.2025.01063

Summary Full Text (PDF)